Addressing ulcerative colitis
A chronic inflammatory bowel disease, ulcerative colitis causes inflammation and ulcers in the large intestine. It is typically underpinned by gut dysbiosis, immune dysregulation and oxidative stress.
A recent review has highlighted the potential of fucoidans to assist in the future treatment of ulcerative colitis. The paper emphasises the ability of fucoidans to suppress the NF‐κβ signalling pathways to reduce pro-inflammatory cytokines and to regulate TLR-mediated macrophage polarization. It also highlights that fucoidans have repeatedly been shown to enhance intestinal barrier integrity, enhance gut microbiome and suppress pathogens.
In several studies, high purity fucoidans produced by Marinova have previously been shown to significantly reduce gut inflammation and colitis.
The paper, ‘Fucoidan as a therapeutic agent for ulcerative colitis: mechanism of action and modulation of the gut microbiome’, was published in Frontiers in Cellular and Infection Microbiology.